Last updated on May 2020

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Brief description of study

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Clinical Study Identifier: NCT03732677

Find a site near you

Start Over

Research Site

Osaka-shi, Japan
  Connect »

Research Site

Osakasayama-shi, Japan
  Connect »